NDAOPHTHALMICSOLUTION/DROPS
Approved
Jul 1953
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
OPHTHAINE (proparacaine hydrochloride) by Bristol Myers Squibb is clinical pharmacology proparacaine hydrochloride ophthalmic solution is a rapidly-acting topical anesthetic, with induced anesthesia lasting approximately 10-20 minutes. First approved in 1953.
Drug data last refreshed 15h ago · AI intelligence enriched 4d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
OPHTHAINE (proparacaine hydrochloride) is a rapidly-acting topical anesthetic ophthalmic solution approved in 1953 for use in ophthalmologic procedures. It induces local anesthesia lasting approximately 10-20 minutes when applied as drops to the eye. The drug is indicated for topical anesthesia during diagnostic and minor surgical ophthalmic procedures.
LOE Approaching
As a legacy product approaching loss of exclusivity with moderate competitive pressure (30%), commercial teams are likely focused on efficiency and cost management rather than expansion.
Mechanism of Action
CLINICAL PHARMACOLOGY Proparacaine hydrochloride ophthalmic solution is a rapidly-acting topical anesthetic, with induced anesthesia lasting approximately 10-20 minutes.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on OPHTHAINE offers limited career growth opportunities given its mature lifecycle and approaching loss of exclusivity. Roles available are primarily in sustainment, commercial efficiency, and compliance rather than innovation or expansion.
Brand ManagerField Sales Representative
Worked on OPHTHAINE at Bristol Myers Squibb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.